Jeffrey V. Poulton
CIK: 0001782962
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (105 total)
- Jun 8, 2026CRVO
CervoMed Inc.
Award(A)DirectStock Option (Right to Buy)
8.2K shares- - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct223 shares at avg. $325.67$73K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct230 shares at avg. $320.81$74K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct309 shares at avg. $321.82$99K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct818 shares at avg. $323.84$265K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct291 shares at avg. $324.88$95K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct109 shares at avg. $320.01$35K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct114 shares at avg. $319.03$36K - Mar 4, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct374 shares at avg. $323.01$121K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct112 shares at avg. $330.85$37K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct356 shares at avg. $325.63$116K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct541 shares at avg. $326.81$177K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct454 shares at avg. $327.67$149K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct124 shares at avg. $324.65$40K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct4.8K shares- - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct53 shares at avg. $332.64$18K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct138 shares at avg. $328.71$45K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct129 shares at avg. $331.93$43K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct65 shares at avg. $323.62$21K - Mar 2, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct234 shares at avg. $329.71$77K - Feb 27, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Exercise(M)Direct1.9K shares- - Feb 13, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct2.2K shares at avg. $310.08$695K - Feb 12, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct4.6K shares- - Jan 12, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct72 shares at avg. $353.95$25K - Jan 12, 2026ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct78 shares at avg. $355.16$28K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 8, 2026 |  CRVO CervoMed Inc. | Award(A) Stock Option (Right to Buy) | 8,150 | - | - | Direct |
| Mar 4, 2026 |  ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 223 | $325.67 | $72,624 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 230 | $320.81 | $73,786 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 309 | $321.82 | $99,442 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 818 | $323.84 | $264,901 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 291 | $324.88 | $94,540 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 109 | $320.01 | $34,881 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 114 | $319.03 | $36,369 | Direct |
| Mar 4, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 374 | $323.01 | $120,806 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 112 | $330.85 | $37,055 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 356 | $325.63 | $115,924 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 541 | $326.81 | $176,804 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 454 | $327.67 | $148,762 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 124 | $324.65 | $40,257 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 4,769 | - | $0 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 53 | $332.64 | $17,630 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 138 | $328.71 | $45,362 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 129 | $331.93 | $42,819 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 65 | $323.62 | $21,035 | Direct |
| Mar 2, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 234 | $329.71 | $77,152 | Direct |
| Feb 27, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Exercise(M) | 1,908 | - | $0 | Direct |
| Feb 13, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 2,242 | $310.08 | $695,201 | Direct |
| Feb 12, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 4,579 | - | $0 | Direct |
| Jan 12, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 72 | $353.95 | $25,484 | Direct |
| Jan 12, 2026 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 78 | $355.16 | $27,702 | Direct |
1-25 of 105 transactions
About Poulton Jeffrey V.
Poulton Jeffrey V. (SEC CIK 0001782962) files insider reports with the SEC as Director of CervoMed Inc. (CRVO) and EVP, Chief Financial Officer of ALNYLAM PHARMACEUTICALS, INC. (ALNY).
Signal8 holds 13 ownership filings by Poulton Jeffrey V., all Form 4s, filed between Nov 27, 2024 and Jun 10, 2026. Those filings report 105 transactions, from Nov 25, 2024 to Jun 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Poulton Jeffrey V.'s filings is in BOSTON, MA.
Recent filings by Poulton Jeffrey V.
- Jun 8, 2026: Grant or award of CRVO derivative securities (Form 4, code A).
- Mar 4, 2026: Open-market sales of ALNY shares (8 lines, Form 4, code S).
- Mar 2, 2026: Open-market sales of ALNY shares (5 lines, Form 4, code S).
- Mar 2, 2026: Grant or award of ALNY shares (Form 4, code A).
- Mar 2, 2026: Open-market sales of ALNY shares (5 lines, Form 4, code S).
Other insiders filing for CervoMed Inc. (CRVO)
- Blackburn Kelly, EVP, Clinical Development
- De Rosch Mark, EVP, RA and GA and PgM
- Winton Matthew, Chief Commercial and Business
- BOGER JOSHUA S, Director
- ZAVRL FRANK, Director
- Sabbagh Marwan, Director